Xerox is probably best known for its copy machines and document management tech. But the company sees a future in medical imaging, too, and recently launched two projects testing the use of video cameras and data analytics to monitor patients at home or remote health clinics.
Smith & Nephew's $1.7 billion bid for ArthroCare may be too low, and some analysts predict that interested rivals will swoop in with a higher offer as a result, Bloomberg reports.
Johnson & Johnson's Ethicon arm lost an early fight ahead of trials alleging that it sold faulty vaginal mesh implants that harmed women. Patients' attorneys had accused the company of inappropriately destroying or losing hundreds of thousands of product documents relating to the issue, and a judge has concluded the allegation is true.
Covidien won the FDA's 510(k) clearance for a high-tech surgical stapling technology, adding another product to its growing portfolio.
A leadless pacemaker, approved for use in Europe, has found its way into its first U.S. patient, St. Jude Medical announced Thursday. Dr. Vivek Reddy implanted the Nanostim leadless pacemaker at The Mount Sinai Hospital in New York, starting a pivotal trial for FDA approval.
Cancer diagnostic test maker Biocept Laboratories finally went public this week, raising $19 million in its initial public offering, selling 1.9 million shares at $10 a piece, according to Renaissance Capital.
As competition mounts in the transcatheter heart valve space, market leader Edwards Lifesciences ($EW) is pursuing at least two options: advancing next generation iterations of its Sapien product line, and wider approved uses for earlier versions.
Boston Scientific CEO Mike Mahoney would like to make hay while the sun shines--and for the medical device giant that means widening the gap between it and its big-three rivals, before billion-dollar rainclouds crack open in the untapped U.S. market for renal denervation.
Thoratec's revenue stagnated at the end of 2013, but net income grew substantially, thanks in part to the effects of a tax credit. The California company's HeartMate pumps continue to provide the bulk of its revenue.
Ichor Medical Systems said it will develop electroporation devices for use in Pfizer's preclinical cancer vaccine research efforts.
Myriad Genetics may be furiously suing competitors who launched rival BRCA predictive cancer diagnostics. But the Utah company was strong enough to produce substantial gains in revenue in its fiscal 2014 second quarter, in part through the success of its own market-dominating BRCA offering.
GE Healthcare sold Breas Medical--its manufacturer of sleep apnea and respiratory ventilators--to PBM Capital Group for an undisclosed price. PBM Capital could not reveal terms of the acquisition, company spokesman Sean Stalfort told FierceMedicalDevices.
Becton Dickinson's net income dropped more than 56% in its fiscal 2014 first quarter, even as revenue grew at a healthy clip. Higher operating costs and the medical device tax prevented better results, the New Jersey med tech company said.
A Michigan startup raised $9.5 million in Series B financing to advance work on its renal denervation hypertension treatment, a device that takes a different approach from Medtronic's market-leading option that flopped in a recent pivotal clinical trial.
Thermo Fisher has closed its mammoth $13.6 billion buyout of Life Technologies, barely a few days after U.S. antitrust regulators signed off on the deal.
Boston Scientific has been known more in recent years for its struggles rather than its successes. But after years of slashing jobs, reorganizing, and diversifying through a number of acquisitions, the Massachusetts device giant appears to be accelerating a turnaround after glimmers of improvement last year.
Endo Health Solutions completed the sale of its HealthTronics urology device business, cleaving off the unwanted segment to Altaris Capital Partners for a deal worth up to $130 million.
On Jan. 2, 2014, a pacemaker was implanted under my right clavicle, with two wire leads snaked through two veins and into my heart. My experience as a patient showed me how limited the true choices are for most U.S. cardiac patients, despite the marketing hype around innovation in the industry.
Children as young as 2 years old can now use the latest in diabetes technology, even as the company that developed it is in a race to make it yesterday's news. The FDA announced Monday it has approved a pediatric version of DexCom's G4 Platinum. The San Diego med tech now has the first continuous glucose monitor (CGM) approved in the U.S. for toddlers.
Rexam, a global maker of beverage cans and other products, will unload most of its healthcare packaging business onto Montagu Private Equity in an $805 million cash deal.